News
IKT
1.370
-32.84%
-0.670
Why Vaxxinity Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Vaxxinity, Inc. (NASDAQ:VAXX) fell sharply during Monday's mid-day session. The company announced its intention to voluntarily delist and deregister its Class A common stock. Matterport, Inc., shares jumped 184% to $4.93.
Benzinga · 19h ago
MRIN, WISA and SMFL among mid-day movers
On the Move MRIN, WISA and SMFL among mid-day movers in SA. Matterport, mF International and Edible Garden AG are among the Gainers. YY Group Holding Limited is one of the losers in SA's top 10 list of companies.
Seeking Alpha · 20h ago
12 Health Care Stocks Moving In Monday's Intraday Session
NKGen Biotech (NASDAQ:NKGN) shares rose 33.8% to $1.48 during Monday's regular session. The company's, Q4 earnings came out 4 days ago. MSP Recovery shares rose 29.74% and Assure Hldgs stock increased by 24.31%. Losers include Vaxxinity, Ocean Biomedical and Telomir Pharmaceuticals.
Benzinga · 20h ago
Weekly Report: what happened at IKT last week (0415-0419)?
Weekly Report · 1d ago
Inhibikase Therapeutics files to sell common stock, warrants
Seeking Alpha · 3d ago
Inhibikase Therapeutics Updates Shareholders on Future Plans
TipRanks · 4d ago
Inhibikase Therapeutics Issues Letter To Shareholders And Provides Update On Development Programs; Says 201 Trial Is ~75% Enrolled
Inhibikase Therapeutics, Inc. Is a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease. The company's 201 trial is approximately 75% enrolled. In a letter to shareholders, the CEO says 2024 is shaping up to be a year of execution for the company.
Benzinga · 4d ago
INHIBIKASE THERAPEUTICS - UPON COMPLETION OF DOUBLE-BLINDED PHASE OF 201 TRIAL, WE EXPECT TO REQUEST AN END OF PHASE 2 MEETING WITH FDA BY END OF 2024
Reuters · 4d ago
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
Inhibikase Therapeutics, Inc. Is a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease. The company issued a Letter to Shareholders on April 18. The company is developing drugs to treat Parkinson's and other diseases.
Barchart · 4d ago
Inhibikase Therapeutics Inc: Other preliminary proxy statements
Press release · 04/15 21:15
Weekly Report: what happened at IKT last week (0408-0412)?
Weekly Report · 04/15 09:44
Weekly Report: what happened at IKT last week (0401-0405)?
Weekly Report · 04/08 09:46
INHIBIKASE THERAPEUTICS INC - MEETING WILL BE HELD ON APRIL 5, 2024, WITH MEETING RESULTS TO BE REPORTED FOLLOWING RECEIPT OF FORMAL MEETING MINUTES
Reuters · 04/03 12:05
Inhibikase Therapeutics Inc: Initial statement of beneficial ownership of securities
Press release · 04/03 06:14
Buy Rating Affirmed for Inhibikase Therapeutics Amid Clinical Advancements and Regulatory Progress
TipRanks · 04/02 19:15
Weekly Report: what happened at IKT last week (0325-0329)?
Weekly Report · 04/01 09:46
Inhibikase Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Inhibikase Therapeutics Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 64 cents per share. The mean expectation of two analysts was for a loss of 85 cents. Reported revenue was zero; analysts expected zero. Shares had risen by 81.1% this quarter.
Reuters · 03/29 13:31
Inhibikase Therapeutics Q4 EPS $(0.64) Beats $(0.85) Estimate, Sales $1.00K Down From $63.57K YoY
Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $0.64 per share. The company beat the analyst consensus estimate by 24.71%. The company reported $1.00 thousand in sales for the quarter, down 98.43 percent from the same period last year.
Benzinga · 03/28 03:45
IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q4 2023
Inhibikase Therapeutics reported earnings per share of -64 cents. This was above the analyst estimate for EPS of -85 cents. The company reported revenue of $1,000. The stock was down 2.7% after the market closed on Wednesday.
Investorplace · 03/28 02:53
More
Webull provides a variety of real-time IKT stock news. You can receive the latest news about Inhibikase Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About IKT
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing therapeutics for Parkinson’s disease and related disorders. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program risvodetinib (also known as IkT-148009), an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson’s disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. Its multi-therapeutic pipeline is pursuing Parkinson’s-related disorders of the brain and GI tract, orphan indications related to Parkinson’s disease such as Multiple System Atrophy, and drug delivery technologies for kinase inhibitors such as IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate. The Company’s RAMP medicinal chemistry program has identified a number of follow-on compounds to IkT-148009 to be potentially applied to other cognitive and motor function diseases of the brain.